Azitra (NYSEAMERICAN:AZTR – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04), FiscalAI reports.
Azitra Price Performance
NYSEAMERICAN AZTR traded up $0.08 during trading hours on Thursday, hitting $0.67. The company had a trading volume of 169,691 shares, compared to its average volume of 1,539,020. The business has a fifty day simple moving average of $1.75 and a 200-day simple moving average of $1.87. Azitra has a fifty-two week low of $0.52 and a fifty-two week high of $4.30.
Azitra Company Profile
Azitra, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company combines microbiology, genetic engineering and computational tools to identify and develop targeted treatments intended to address diseases affecting the skin. Azitra’s platform centers on engineered strains of beneficial skin bacteria and biologic compounds designed to deliver therapeutic proteins or otherwise influence the skin’s local environment. Its development programs have focused on conditions including inflammatory skin disorders, rare genetic diseases and treatment-related dermatologic complications.
See Also
- Five stocks we like better than Azitra
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
